Denali Therapeutics (DNLI) Revenue & Revenue Breakdown
Denali Therapeutics Revenue Highlights
Latest Revenue (Y)
$330.53M
Main Segment (Y)
Alzheimer's Disease Services
Main Geography (Y)
Alzheimer's Disease Services
Denali Therapeutics Revenue by Period
Denali Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $330.53M | 204.74% |
| 2022-12-31 | $108.46M | 122.90% |
| 2021-12-31 | $48.66M | -85.50% |
| 2020-12-31 | $335.66M | 1158.19% |
| 2019-12-31 | $26.68M | -79.34% |
| 2018-12-31 | $129.16M | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Denali Therapeutics generated $330.53M in revenue during NA 2023, up 204.74% compared to the previous quarter, and up 255.91% compared to the same period a year ago.
Denali Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $-305.04M | -24176.01% |
| 2023-09-30 | $1.27M | -99.57% |
| 2023-06-30 | $294.12M | 736.98% |
| 2023-03-31 | $35.14M | 241.74% |
| 2022-12-31 | $10.28M | 188.93% |
| 2022-09-30 | $3.56M | -93.22% |
| 2022-06-30 | $52.48M | 24.53% |
| 2022-03-31 | $42.14M | 236.75% |
| 2021-12-31 | $12.51M | 136.78% |
| 2021-09-30 | $5.29M | -76.96% |
| 2021-06-30 | $22.94M | 189.52% |
| 2021-03-31 | $7.92M | -97.50% |
| 2020-12-31 | $316.81M | 3272.88% |
| 2020-09-30 | $9.39M | 60.65% |
| 2020-06-30 | $5.85M | 62.24% |
| 2020-03-31 | $3.60M | -22.86% |
| 2019-12-31 | $4.67M | -65.66% |
| 2019-09-30 | $13.60M | 224.14% |
| 2019-06-30 | $4.20M | -0.19% |
| 2019-03-31 | $4.21M | -96.65% |
| 2018-12-31 | $125.68M | 10416.82% |
| 2018-09-30 | $1.20M | -27.49% |
| 2018-06-30 | $1.65M | 157.10% |
| 2018-03-31 | $641.00K | -99.56% |
| 2017-12-31 | $145.15M | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | - |
Denali Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Denali Therapeutics Revenue Breakdown
Denali Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Alzheimer's Disease Services | $3.40M | $3.50M | $3.90M |
Denali Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 20: Alzheimer's Disease Services (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|
| Alzheimer's Disease Services | $3.40M | $3.40M | $3.40M | $3.40M | $3.40M | $3.60M | $3.70M | $3.80M |
Denali Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 21: Alzheimer's Disease Services (100.00%).
Denali Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Alzheimer's Disease Services | $3.40M | $3.50M | $3.90M |
Denali Therapeutics's latest annual revenue breakdown by geography, as of Dec 20: Alzheimer's Disease Services (100.00%).
Quarterly Revenue by Country
| Country | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|
| Alzheimer's Disease Services | $3.40M | $3.40M | $3.40M | $3.40M | $3.40M | $3.60M | $3.70M | $3.80M |
Denali Therapeutics's latest quarterly revenue breakdown by geography, as of Jun 21: Alzheimer's Disease Services (100.00%).
Denali Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BGNE | BeiGene | $2.46B | $929.17M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| DNLI | Denali Therapeutics | $330.53M | - |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| TVTX | Travere Therapeutics | $145.24M | $54.12M |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| SWTX | SpringWorks Therapeutics | $5.45M | $21.01M |
| FIXX | Q32 Bio | $1.16M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| DSGN | Design Therapeutics | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| PCVX | Vaxcyte | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| CERE | Cerevel Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| AKRO | Akero Therapeutics | - | - |
| FDMT | 4D Molecular Therapeutics | - | - |
DNLI Revenue FAQ
What is Denali Therapeutics’s yearly revenue?
Denali Therapeutics's yearly revenue for 2023 was $330.53M, representing an increase of 204.74% compared to 2022. The company's yearly revenue for 2022 was $108.46M, representing an increase of 122.90% compared to 2021. DNLI's yearly revenue for 2021 was $48.66M, representing a decrease of -85.50% compared to 2020.
What is Denali Therapeutics’s quarterly revenue?
Denali Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). DNLI's quarterly revenue for Q4 2023 was $-305M, a -24176.01% decrease from the previous quarter (Q3 2023), and a -3066.48% decrease year-over-year (Q4 2022).
What is Denali Therapeutics’s revenue growth rate?
Denali Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 579.25%, and for the last 5 years (2019-2023) was 1138.96%.
What are Denali Therapeutics’s revenue streams?
Denali Therapeutics's revenue streams in c 20 are Alzheimer's Disease Services
What is Denali Therapeutics’s main source of revenue?
For the fiscal year ending Dec 20, the largest source of revenue of Denali Therapeutics was Alzheimer's Disease Services. This segment made a revenue of $3.4M, representing 100.00% of the company's total revenue.